Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice